-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationTom Lee
Pfizer CEO Albert Bourla said in an interview with CNBC television in the US on Monday that Pfizer now expects to produce 80 million courses of the COVID drug Paxlovid by the end of 2022
External analysis believes that an important reason for Pfizer's decision to increase production capacity is the failure of competitors' trials
The less-than-expected test results stimulated expectations of increased demand for Paxlovid, which showed that the risk for outpatients was reduced by 89%
The emergence of the new coronavirus variant omicron has once again raised concerns about the power of existing vaccines and therapies
The SARS-CoV-2 coronavirus uses the spike protein on its surface to infect healthy cells, and Paxlovid is a protease inhibitor designed to block the enzymes required for virus replication
However, the premise of all these expectations is that Pfizer Paxlovid's efficacy data are true and reliable
Reference source:
1.
2.